8. Computed Tomography (CT) Scan: CT scan eyinza okukozesebwa okukebera oba kkansa esasaana mu bitundu by'omubiri ebirala oba mu nsigo.
Kikulu okukijjukira nti si buli musajja alina omuwendo gwa PSA omunene oba ebivuddemu bya DRE ebitaali bya bulijjo ajja kuba n'akawuka ka prostate, era si buli kawuka ka prostate kajja kuvaamu omuwendo gwa PSA omunene.
Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.
Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.
Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.
Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.
McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.
An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.
[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.
Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.
Okwewala obuvunaanyizibwa: eby'obujjanjabi
Omukutu guno guweereddwa olw'ebigendererwa by'enjigiriza n'obubaka bwokka era teguwa kubuulirira kw'ekisawo oba obuweereza bw'ekikugu.
Obubaka obuweereddwa tebusaanidde kukozesebwa okuzuula oba okujjanjaba bulwadde, era abo abanoonya amagezi g'ekisawo balina okwebuuza ku musawo alina layisensi.
Weetegereze nti enkola ya neural net ekola eby'okuddamu mu bibuuzo, si ntuufu nnyo bwe kituuka ku muwendo gw'abantu. Ng'ekyokulabirako, omuwendo gw'abantu abalwadde obulwadde obumu.
Bulijjo noonya amagezi g'omusawo wo oba omusawo omulala omutuufu ku bikwata ku mbeera y'obulamu. Teweerabira magezi g'omusawo oba okulwawo okuganoonya olw'ekintu ky'osomye ku mukutu guno. Bw'oba olowooza oyinza okuba n'embeera ey'amangu mu by'obulamu, yita 911 oba genda mu ddwaaliro ly'amangu erisinga okumpi amangu ddala. Tewali nkolagana ya musawo n'omulwadde ekolebwa ku mukutu guno oba okukozesawo. BioMedLib oba abakozi baagwo, oba omuntu yenna ayamba ku mukutu guno, talina ky'agamba, ekyogamba oba ekiteeberezebwa, ku bikwata ku bubaka obuli wano oba okukozesawo.
Okwewala obuvunaanyizibwa: eddembe ly'okuwandiika
Digital Millennium Copyright Act ey'omwaka 1998, 17 U.S.C. § 512 (DMCA) ewa abalina eddembe ly'okuwandiika ebitabo abakkiriza nti ebintu ebiri ku mutimbagano bikontana n'eddembe lyabwe wansi w'amateeka g'eddembe ly'okuwandiika ebitabo mu Amerika.
Bw'oba olowooza mu bwesimbu nti ebintu oba ebintu ebikolebwa ku mukutu gwaffe ogwa webusayiti oba obuweereza bikontana n'amateeka go ag'eddembe ly'obuntu, ggwe (oba omubaka wo) osobola okututumira obubaka ng'osaba ebintu oba ebintu ebyo biggyibwe, oba okukugira.
Okumanyisa kulina okusindikibwa mu buwandiike nga bakozesa e-mail (laba ekitundu "Contact" ku adirisa ya e-mail) .
DMCA yeetaaga nti ekiwandiiko kyo eky'okuvumirira obutali bwenkanya bw'eddembe ly'obuntu kitwaliramu obubaka buno: (1) okunnyonnyola omulimu oguli wansi w'eddembe ly'obuntu ogugambibwa obutali bwenkanya; (2) okunnyonnyola ebintu ebigambibwa obutali bwenkanya n'obubaka obumala okutusobozesa okuzuula ebintu ebyo; (3) obubaka bw'okuwuliziganya naawe, nga mw'otwalidde endagiriro yo, ennamba ya ssimu n'ennamba ya e-mail; (4) ekiwandiiko okuva gy'oli ekiraga nti olina okukkiriza okutuufu nti ebintu mu ngeri ey'okwemulugunya tebikkirizibwa nnannyini ddembe ly'obuntu, oba omubaka we, oba mu nkola y'amateeka.
(5) ekiwandiiko ky'oyimirizza, wansi w'omusango gw'okubuusabuusa, nti obubaka obuli mu kiwandiiko kituufu era nti olina obuyinza okussa mu nkola eddembe ly'okuwandiika erigambibwa okuba nga lyamenyebwa;
era (6) omukono ogw'omubiri oba ogw'oku mutimbagano ogwa nnannyini copyright oba omuntu ow'obuyinza okukolera mu linnya lya nnannyini copyright.
Prostate cancer is diagnosed through a combination of tests and procedures, which may include:
1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.
2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.
Elevated PSA levels may indicate the presence of prostate cancer.
3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.
This can help identify any abnormalities in the prostate gland.
4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.
This is the only definitive way to diagnose prostate cancer.
5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.
6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.
7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.
8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.
It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.
Therefore, a biopsy is necessary to confirm the diagnosis.
Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
